These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 25579165

  • 1. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL, Langabeer SE, Bolger K, Haslam K, Crampe M, Kelly J, Morrell R.
    Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
    [Abstract] [Full Text] [Related]

  • 2. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
    Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC, SAKK and the German CML Study Group.
    Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
    [Abstract] [Full Text] [Related]

  • 3. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ.
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [Abstract] [Full Text] [Related]

  • 4. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 5. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
    Li C, Wang Y, Xu D, Zhang P, Ding X, Zhang N, Xiao M, Huang L, Meng L.
    Clin Lab; 2015 Sep 05; 61(1-2):183-6. PubMed ID: 25807654
    [Abstract] [Full Text] [Related]

  • 6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Sep 05; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 7. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 05; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 8. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
    Snyder DS, McMahon R, Cohen SR, Slovak ML.
    Am J Hematol; 2004 Feb 05; 75(2):92-5. PubMed ID: 14755375
    [Abstract] [Full Text] [Related]

  • 9. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE.
    Haematologica; 2009 Oct 05; 94(10):1362-7. PubMed ID: 19713230
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ.
    Br J Haematol; 2018 Sep 05; 182(5):693-700. PubMed ID: 29974949
    [Abstract] [Full Text] [Related]

  • 11. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
    Togitani K, Asagiri T, Kamioka M, Kojima K.
    Rinsho Ketsueki; 2021 Sep 05; 62(3):180-185. PubMed ID: 33828011
    [Abstract] [Full Text] [Related]

  • 12. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 Sep 05; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 13. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G, GIMEMA CML Working Party.
    Am J Hematol; 2017 Aug 05; 92(8):797-805. PubMed ID: 28466557
    [Abstract] [Full Text] [Related]

  • 14. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP.
    Blood; 2013 May 09; 121(19):3818-24. PubMed ID: 23515925
    [Abstract] [Full Text] [Related]

  • 15. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S.
    J Cancer Res Clin Oncol; 2015 May 09; 141(5):887-99. PubMed ID: 25367136
    [Abstract] [Full Text] [Related]

  • 16. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH, Abu-Amero KK, Al Mohareb F, Chaudhri NA.
    Genet Test Mol Biomarkers; 2010 Feb 09; 14(1):67-74. PubMed ID: 19943786
    [Abstract] [Full Text] [Related]

  • 17. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
    Marcé S, Cortés M, Zamora L, Cabezón M, Grau J, Millá F, Feliu E.
    Exp Mol Pathol; 2015 Aug 09; 99(1):16-8. PubMed ID: 25913326
    [Abstract] [Full Text] [Related]

  • 18. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC, Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH.
    Leuk Res; 2013 Jan 09; 37(1):43-9. PubMed ID: 23062378
    [Abstract] [Full Text] [Related]

  • 19. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
    Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP.
    Blood; 2014 Jul 24; 124(4):511-8. PubMed ID: 24859364
    [Abstract] [Full Text] [Related]

  • 20. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
    Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC.
    J Clin Oncol; 2012 Dec 10; 30(35):4323-9. PubMed ID: 23109697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.